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ABSTRACT
Introduction: The authors investigated whether 
a new ginkgo biloba (ginkgo) fresh plant extract 
had a positive effect on microcirculation in 
the skin and liver of elderly individuals, and 
whether the extract had antioxidative properties 
in vivo. Methods: In a monocentric, controlled 
clinical trial with 32 elderly patients, 16 patients 
received three 90 mg ginkgo extract tablets 
twice daily for 30 days, and 16 patients acted 
as untreated controls. On days 0, 10, 20, and 
30, microcirculatory parameters were measured 
using intravital microscopy in combination 
with reflection spectrometry, and the amount 
of reduced glutathione in the liver. Results:
This new ginkgo fresh plant extract significantly 
increased the number of blood cell-perfused 
nodal points, the venular streaming flow, and 
the local hematocrit in treated participants 
compared to control participants and compared 
to values on day 0. The ginkgo preparation also 
increased microcirculation in the liver, and 
possessed antioxidative properties that resulted in 
significant increases in the amount of the radical 
scavenger glutathione in treated participants. 
Conclusion: The new ginkgo fresh plant extract 
increased the microcirculation significantly, 
and at the same time improved the radical 
scavenging capacity in elderly patients and was 
very well tolerated. This extract is an interesting 
adjuvant treatment option for patients suffering 
from impaired microcirculation and improves 
mechanisms which inhibit an accelerated 
expression of atherosclerosis.
Keywords: clinical trial; ginkgo biloba; 
ginkgoaceae; glutathione; liver; microcirculation 
INTRODUCTION
Preparations of ginkgo biloba (ginkgo) are 
among the most widely researched and 
top-selling phytopharmaceuticals,1 and are 
often used in elderly patients. Ginkgo has 
been investigated for the treatment of mild-
to-moderate dementia symptoms, its ability to 
increase mental performance, and for cerebral 
insufficiency, tinnitus, vertigo, and peripheral 
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arterial occlusive disease.2 The mode of action 
of ginkgo varies; in animal experiments, ginkgo 
preparations showed vasoregulatory activity,3
leading to improved rheological properties in 
the blood. In humans, individuals with ginkgo 
had enhanced peripheral and coronary blood 
flow as a result of endothelium-dependent 
vasodilation.4 Furthermore, more than 20 papers 
have described the in vitro antioxidative effects 
of gingko, which appears to protect endothelial 
cells.5 However, ginkgo also inhibits platelet-
activating factors, decreases the age-related 
loss of muscarinic cholinoreceptors, stimulates 
choline uptake in the hippocampus, and inhibits 
beta-amyloid deposition.6
Several studies have investigated the ability of 
ginkgo to increase the microcirculatory perfusion 
of blood vessels. In rats, cerebral microcirculation 
after subarachnoid hemorrhage,7 as well as the 
hepatic microcirculation in warm ischemia,8 was 
increased after intravenous or oral administration 
of ginkgo extract, and ginkgo may also have a 
protective effect on hepatic microcirculation in 
rats with induced liver injuries.9
Two clinical trials in elderly patients 
with either pathological viscoelasticity 
values10 or poor cerebral circulation11 showed 
that intravenous application of a ginkgo 
extract lead to a dose-dependent increase 
in microcirculation in the skin after acute 
application, or in the bulbar conjunctiva after 
10-15 days. Two trials with orally administered 
ginkgo tablets in healthy volunteers showed 
an increase in cutaneous microcirculation after 
acute intake,12 and an increase in forearm blood 
flow after 6 weeks.13
Currently, most studies use a single 
standardized ginkgo extract using acetone as 
an extractant (60%) and with a drug extraction 
ratio of 35-67:1. The authors developed a new 
ginkgo extract made from fresh leaves using a 
more traditional approach by using ethanol 
65% as extractant and with a drug extraction 
ratio of 3-5:1. This extract was shown to have 
positive effects on retinal blood flow in healthy 
volunteers after acute application in a clinical 
pilot trial.14 In the present clinical trial, the 
authors evaluated whether the new ginkgo 
extract would improve microcirculation in 
elderly individuals during a 30-day time period. 
To the authors knowledge, this is the first 
trial on ginkgo to assess not only changes in 
the microcirculation of the gingiva or skin in 
response to ginkgo, but also in a large inner 
organ such as the liver. Moreover, the authors 
believe that this is also the first investigation 
of whether the antioxidant activity of ginkgo 
observed in vitro can be demonstrated in vivo by 
measuring the amount of reduced glutathione. 
MATERIALS AND METHODS
Patients
Inclusion criteria were ambulant geriatric patients 
of both genders, White, aged 60-70 years with 
no acute pathological conditions; concomitant 
treatments of the usual clinical categories 
for multi-morbid patients were permitted 
(eg, heart glycosides, antihypertensive agents, 
and diabetes medication). Other inclusion criteria 
were chronic disorders that were only slightly or 
moderately severe in character, no pathological 
acute diagnosis, free of common colds for 4 weeks, 
no physical or mental disabilities, adherence to 
study protocol, balanced character, and written 
informed consent. 
Exclusion criteria were heavy smoking 
(>10-15 cigarettes/day), alcohol and drug abuse, 
participation in another clinical trial in the 
previous 90 days, concomitant participation 
in another clinical trial, psychiatric diseases, 
epilepsy, suicidal tendencies, blood donation 
or blood loss >500 mL within the last 
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6 months, body weight not within ± 10% of 
the corresponding height, sex, and body type 
as described in the Metropolitan Life Insurance 
Company Tables 1983 or Broca index >150%, 
or overweight (>20% of normal weight), 
consumption of unusually large amounts of 
coffee or tea (more than 1 liter/day), according 
to the judgment of the investigator, individuals 
on weight-loss diets or with unbalanced diets, 
defined as diets which may lead to health 
hazards (ie, junk food, etc); chronic liver disease 
(two-fold normal value of transaminases), 
renal disorders (increase in serum creatinine 
>1.2 mg or creatinine clearance <50 mL/minute), 
number of leukocytes <3500/μL, number of 
thrombocytes <100,000/μL, suspected severe 
intestinal, pulmonary, or bronchial disorders; 
and severe parodontopathies. Patients with any 
other severe diseases were also excluded. 
Study Medication 
Patients were issued one bottle with 180 tablets 
and told to take three tablets with water twice 
daily; once in the morning and once in the 
evening. Each tablet contained 90 mg of native 
extract (Batch No. 011301, Drug Extraction Ratio 
3-5:1 calculated from the dried plant; extractant 
65% ethanol V/V) of fresh ginkgo biloba leaves 
from a certified cultivation in France (batch 
number 009396) (A. Vogel Bioforce AG, Roggwil, 
Switzerland). The cultivation complies with the 
standards of Good Agricultural Practice (GAP); 
no voucher specimen has been kept. The extract 
contained <100 ppm ginkgolic acid and one 
tablet of 90 mg had 2.1% flavonol glycosides, 
494 μg bilobalide, 220 μg ginkgolide A and 
131 μg ginkgolide B. The fingerprint from the 
high-performance liquid chromatography 
(HPLC) analysis is given in Figure 1.
Study Conduct, Measurements, and 
Parameters
This was a controlled, nonblinded, parallel-
group, monocentric clinical trial. The study 
included 32 participants; 16 participants received 
the test medication, and 16 participants acted 
as untreated controls. The study center was the 
Institute for Microcirculation in Berlin, Germany, 
and the trial was carried out in July and August 
2004 in accordance with the guidelines of good 
clinical practice and the ethical obligations of 
the Declaration of Helsinki.
Eligible participants were investigated at 
day 0 which served as the baseline value, and 
at days 10, 20, and 30. Two hours prior to the 
investigation, participants were not allowed 
to drink alcohol, coffee, tea, or caffeinated 
carbonated beverages, they were to have had at 
least 6 hours of sleep the previous night, and 
sufficient acclimatization and rest (normal blood 
pressure, respiratory rate, and heart frequency). 
The measurements were taken while the 
participants were seated. 
The applied investigative method was 
intravital microscopy in combination 
with reflexion spectrometry. The intravital 
microscopy investigation unit used a combined 
illuminating and radiating process with selective 









































Figure 1. High-performance liquid chromatography 
(HPLC) fingerprint of ginkgolides and bilobalide from the 
ginkgo fresh plant extract.
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(Zeiss and Nikon microscopes with a Kontron 
system [manufactured by Kontron, Eching, 
Germany]). The reflexion spectrometric 
investigations were carried out with the Spex 
System (Spex Industries, Edison, New Jersey, USA). 
Microphotography up to 1/8,000 s, super-Home 
Video System (S-VHS), and U-matic and cinema 
film with image frequencies up to 120 images/s 
(ARRI [Arnold & Richter Cine Technik, München, 
Germany] system) supported the documentation. 
A more detailed description of the instruments, 
methods, and technologies that were used in this 
study can be found in other papers.15,16
The target tissue was either a defined region 
of the subcutis of the lower left arm or of the 
oral mucosa (gingiva) with a volume of about 
1200 μm3. The authors assessed connected and 
complete microvascular networks that were 
perfused and had a defined target volume of 
about 1 mm3 with 60 Kirchoff junctions (nodal 
points [nNP]) and with an average microvessel 
diameter of >40 μm. 
The authors assessed the following parameters 
by vital microscopy as microcirculatory 
parameters: 1) number of blood cell-perfused nNP 
in a defined network unit; 2) venular streaming 
flow (Qven); and 3) microcirculation hematocrit 
(HkMZ). To assess if ginkgo had an influence on 
the number of leukocytes which could be found 
in a defined region, the authors also measured 
the number of adhering white blood cells on 
a defined inner venule wall (nWBC/A), and the 
relative concentration of intercellular adhesion 
molecule in the white blood cells (CICAM-1).
For a subgroup of 24 randomly selected 
participants (12 treated and 12 untreated; each 
group contained six men and six women), the 
following measurements were also made in the 
liver parenchyma (lower right costal arch, defined 
tissue volume unit V = 1200 μm3): current flow in 
the sinusoids (Qsin) (absolute amounts), and total 
cross section of the sinusoidal channel (Asin). 
To assess whether ginkgo had antioxidative 
properties in vivo, the local amount of reduced 
and oxydated glutathione (CGI-red) in the liver was 
measured. It is particularly rich in glutathione 
which acts as one of the strongest antioxidants 
in the human body.
At the end of the treatment period, the 
participants were assessed to determine if their 
condition had improved, remained the same, or 
worsened. In addition, participants reported any 
adverse events at each visit. 
Statistical Analysis
The authors determined the differences within 
both groups between the different time points 
(10, 20, and 30 days) and the baseline values at 
day 0. The differences between the treatment 
and control groups at each of the time points 
with the Wilcoxon rank sum test were also 
determined. Tests were carried out with a 
significance level of α=0.05 (two-sided), and the 
critical values for t were taken from Ferguson.17
RESULTS
Demographic Data
The demographic data of the study population 
are listed in Table 1. The treatment and control 
groups were similar in age, height, weight, body 
mass index, and gender distribution, and were 
therefore comparable. All of the participants 
came to all of the study visits, and in the 
treatment group they were fully compliant 
regarding intake of the study medication. 
Efficacy and Safety Parameters
The mean number of blood cell-perfused nNP 
increased in the ginkgo group from 60 to 64.3 ± 2.5 
in the defined network unit after 30 days of 
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treatment (P<0.05), while the values in the 
control group remained almost stable (from 
60 to 58.4 ± 2.9 nNP). From day 10 onward, the 
values in the ginkgo group compared to the 
control group were statistically significantly 
different (P<0.05) (Figure 2).
From day 20 of treatment onward, the Qven
in the ginkgo group was significantly greater 
compared to day 0 (P<0.05), and also compared 
to the control group (P<0.05) (Figure 3). 
The HkMZ remained almost stable in the 
control group, but it had decreased by 5.4% in 
the ginkgo group by day 30. In comparison to 
the control group, decreases in the HkMZ in the 
ginkgo group were statistically significant from 
day 10 onward (P<0.05).
To measure if the ginkgo treatment had an 
influence on the number of leukocytes in a 
vessel, the number of adhering white blood cells 
in a defined inner venule wall were counted. 
The nWBC/A had increased significantly after 
20 days in the ginkgo group (P<0.05); 
furthermore, the CICAM-1 was significantly higher 
compared to both the baseline value and to the 
Table 1. Demographic data.
Control Ginkgo 
Number of patients 16 16
Number of men/women 8/8 8/8
Average age (mean ± SD) 65.4 ± 2.7 65.5 ± 2.76
Body weight (mean ± SD) 75.6 ± 3.03 75.0 ± 3.18
Height (mean ± SD) 172.3 ± 2.35 172.3 ± 2.33
BMI men (mean ± SD) 25.56 ± 1.31 25.5 ± 0.96




















Figure 2. Number of blood perfused nodal points (nNP) 
in a defined network unit during the treatment period of 
30 days in participants taking ginkgo tablets (n=16) and 
in untreated controls (n=16). *A statistically significant 





























Figure 3. Venular streaming flow (Qven) in a defined 
network unit during the 30-day treatment period in 
participants taking ginkgo tablets (n=16) and in untreated 
controls (n=16). *A statistically significant difference 
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control group (P<0.05), which corresponded well 
with the nWBC/A number of artering leukocytes.
All of the parameters described above 
were assessed in the subcutis; by measuring 
immediately under the right costal arch, 
the authors were also able to investigate 
microcirculation in the liver. There was a 
significant difference in the Qsin in the ginkgo 
and the control groups from day 20 onward 
(P<0.05) (Figure 4). An example of the change 
in Qsin for a participant in the treatment group 
is illustrated in Figure 5. For the cross section 
of the Asin sinusoidal channel, no significant 
differences in characteristics between the ginkgo 





















Figure 4. Relative changes in current flow in the sinusoids  
(Qsin) in the liver in a defined network unit during the treatment 
period of 30 days in participants taking ginkgo tablets (n=16) 
and in untreated controls (n=16). *A statistically significant 
difference between the ginkgo and control group (P<0.05).
Figure 5. Vital microscopic examples of the functional condition of hepatic microcirculation; ie, diameter of the sinusoid 
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the ginkgo group there were significant changes 
between day 0 and day 10 onward (P<0.05). 
To assess changes in antioxidative properties, 
the authors measured the amount of reduced 
hepatic glutathione CGI-red. Ginkgo appeared 
to improve the antioxidative capacity of the 
body: after 10 days, there was an increase in 
the CGI-red, which continued to increase up to 
day 30, and was significantly different from the 
baseline value and the control group from day 
20 onwards (P<0.05) (Figure 6).
Of the 16 patients in the control group at the 
end of the treatment, 11 described their state of 
health as unchanged, four described it as worse, 
and one described it as improved. In the ginkgo 
group, five participants described their state 
as unchanged, two described it as worse, and 
nine described it as improved. The tablets were 
well tolerated and no side effects were reported 
during the treatment period. 
DISCUSSION
Although previous trials have shown that 
intravenously or orally administered ginkgo 
preparations have a positive effect, particularly 
on dermal microcirculation,11-13 to the authors 
knowledge, this was the first trial to find 
improvement in a variety of microcirculation 
parameters in the skin and gingiva. The number 
of perfused nNP rose, and the venular streaming 
flow and hematocrit of microcirculation 
increased significantly compared to baseline 
and control values, generally after 10-20 days of 
taking the ginkgo fresh plant tablets. 
In addition, this study demonstrated for the 
first time that a ginkgo preparation enhanced 
the microcirculation of the liver, an example 
of a large inner organ. This suggests that 
microcirculation in the entire body may be 
augmented. The authors also found that in the 
ginkgo treatment group, the amount of reduced 
glutathione in the liver was doubled, suggesting 
an increase in antioxidative action. 
Nevertheless, the trial also has several 
limitations. The patient population was rather 
small and restricted to elderly patients and the 
treatment duration was, at 30 days, quite short. 
A larger, longer lasting trial with a younger 
population would be warranted to show if a 
generally younger population would experience 
the same effects as in this trial, and if a longer 
treatment with the ginkgo fresh plant tablets 
would lead to even better results. The mode of 
action of increased microcirculation caused by 
ginkgo is not fully understood. 
In rats, an increase in blood perfusion after 
ginkgo application was attributed to regulation 
of the precapillary sphincter and to dilation 
of perfusion capillaries,18 and in the blood of 
eight patients taking a ginkgo preparation for 
2 months, concentrations of the vasodilating 
molecules, cyclic adenosine monophosphate 
(cAMP), and cyclic guanosine monophosphate 
(cGMP) were significantly increased compared 
to baseline.19 The extent to which inhibition 
of a platelet activating factor (PAF)20 and the 



















Figure 6. Amount of reduced glutathione measured in the 
liver in a defined network unit during the treatment period 
of 30 days in participants taking ginkgo tablets (n=16) and 
in untreated controls (n=16). *A statistically significant 
difference between the ginkgo and control group (P<0.05).
* *
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a role in improved microcirculation remains a 
topic of discussion.5
The active constituents of ginkgo that are 
responsible for its pharmacological effects 
are mostly flavonoids, terpenoids, such as 
ginkgolide A, B, and C, and bilobalides.2
Although ginkgo was used traditionally as 
a tea,21 alcoholic tincture,22 or extract, just 
one extract has been used in most clinical 
trials and research: the standardized ginkgo 
special extract EGb761 (DER 35-67:1, producer 
Dr. Willmar Schwabe GmbH, Karlsruhe, 
Germany). In this trial, a new extract was 
used made from fresh leaves from ginkgo 
with ethanol as an extractant, which is a 
more traditional way to produce a herbal 
preparation. In a previous study, administration 
of this extract was associated with a significant 
improvement in the retinal capillary blood 
flow after 1 hour in eight healthy volunteers.14
In a bioavailability trial, the extract displayed 






























Figure 7. Scheme of the production of free oxygen radicals and their elimination and detoxification by superoxide dismutase 
(SOD), catalase, and glutathione peroxidase. Increased amounts of reduced glutathione (two glutathione [GSH]) are mostly 
caused by SOD upregulation. GSSG=glutathione disulphide; NADPH=nicotinamide adenine dinucleotide phosphate; 
OH=hydroxide; ONOO=peroxynitrite. Diagram adapted from Siegel et al.19 with friendly permission of Springer Verlag, 
Vienna, which also owns the copyright for this figure.
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(bilobalide and ginkgolide A and B) that were 
similar to the standardized extract; these 
constituents may be the basis for the rapid 
increase in retinal blood flow.23 In another 
trial in elderly patients with age-related 
non-Alzheimer mild cognitive impairment, 
daily intake of two tablets containing 
90 mg each of the ginkgo fresh plant extract 
was associated with an improvement in the 
SF-12 quality-of-life mental health subscore. 
Furthermore, treated patients had decreased 
memory impairment and increased ability 
to concentrate; in this study, the extract was 
well tolerated.24 The study on the retinal 
blood flow14 showed a good efficacy between 
90 and 270 mg extract, and the bioavailability 
trial showed a higher amount of active 
constituents in the blood than as if a patient 
would take a ginkgo tincture.23 Thus, a dosage 
scheme of 2x 90 mg extract daily was chosen, 
which proved to be safe and effective in the 
above mentioned trial in elderly patients.24
An important finding of this study was that 
the ginkgo preparation used was associated 
with a two-fold increase in the amount of 
reduced gluthathione in the liver, indicating 
antioxidant activity. Glutathione is a specific, 
low molecular weight thiol (SH) group 
carrier; two molecules of glutathione become 
one double molecule linked by a disulfide 
bridge, by means of reversible oxidation. The 
unreduced and reduced forms of glutathione 
are an important cellular oxidation-reduction 
system, particularly in liver cells.25 Details 
about the formation of glutathione are 
outlined in Figure 7.19 The effect of the ginkgo 
extract on glutathione is in line with the 
findings of Rodriguez et al.,26 who found that 
the activity of superoxide dismutase (SOD) 
was upregulated by 15.7% on average after a 
2 month application of 240 mg of Egb761/day 
in eight patients, leading to a reduced ratio 
of oxidized low-density lipoprotein (LDL) 
to normal LDL, and a higher concentration 
of lipoprotein (a). Based on their results, 
Rodriguez et al. saw potential for ginkgo as 
an adjuvant treatment for atherosclerosis 
prevention in predisposed patients.
The improved microcirculation observed 
in the current study has several clinical 
implications: impaired microcirculation 
can be a precondition or manifestation of 
numerous pathologies, such as chronic venous 
insufficiency,27 hypertension, insulin resistance, 
and sepsis,28 and it is believed to play a role in 
metabolic syndrome,29 Raynaud syndrome,30
and erectile dysfunction.31 Microcirculation 
is generally decreased in smokers,32 and most 
likely also in patients with cognitive disorders.33
Furthermore, as people age, perfusion decreases; 
thus, elderly persons in particular have impaired 
microcirculation.34 Ginkgo has a very good safety 
record2,21 and the good tolerability of this ginkgo 
extract has been seen in all the trials which have 
been carried out so far.14,23,24 Thus, taking ginkgo 
to improve perfusion of the capillary networks 
in the entire body may be a good preventative 
measure or an adjuvant treatment option for 
people with impaired microcirculation. 
CONCLUSION
The authors found that a new ginkgo fresh plant 
extract improved microcirculation significantly, 
and increased the body’s ability to scavenge free 
radicals. The treatment was well tolerated and 
accepted by the patients. This new ginkgo extract 
may be an interesting complementary treatment 
option in patients suffering from diseases 
in which decreased microcirculation plays a 
pivotal role. In addition, because it boosts the 
body’s radical scavenging properties, it should 
be considered as an adjuvant preventative 
treatment for atherosclerosis.
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